TKI

Org: Friends of Cancer Research, Washington, DC, NMD Group, Cancer Research and Biostatistics, Guardant Health, Inc., Takeda Pharmaceuticals U.S.A., Inc.,

Abstract

Biomarker-driven prospective clinical trial in renal cell carcinoma: Developing machine learning models to allocate patients to treatment arms using RNA sequencing.

Org: Vindhya Data Science, Durham Veteran Affairs Medical Center, NC Medical Research, Vanderbilt University Medical Center, Nashville,

Abstract

Microbial metabolism of tryptophan is associated with resistance to immune checkpoint (ICB) therapy in renal cell cancer (RCC).

Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine, Moffitt Cancer Center, Tampa General Hospital,

Abstract

CfDNA NGS detection of fusions acquired as mechanisms of resistance in the post-EGFR setting across multiple solid tumors.

Org: Guardant Health Inc., Palo Alto University, CanSino Biologics, Guardant Health, Inc., Redwood City, CA,

Abstract

Effect on outcomes of toxicity-related dose reduction in TKI monotherapy or TKI-IO combination therapy for advanced renal cell carcinoma.

Org: Department of Experimental, Diagnostic, and Specialty Medicine, S.Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Bologna, Italy, Vall d'Hebron University Hospital, Barcelona, Spain, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy, Bologna, Italy, Medical Oncology Unit, Macerata General Hospital, Macerata, Italy, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Hospital Universitari Vall d'Hebron, Barcelona, Spain, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy, Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain,

Abstract

Use of a systems-biology informed machine learning model to predict drug response using clinically available NGS data.

Org: Zephyr AI, Mclean, VA,

Abstract

Dynamic ctDNA to inform the precise management of resected NSCLC: LUNGCA-2 study.

Org: Institute of Thoracic Oncology and Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China, Department of Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, China, Genecast Biotechnology Co., Ltd, Wuxi, China, Department of Thoracic surgery,Sichuan Provincial People's Hospital, Chengdu, China, Department of Thoracic Surgery, Chengdu Shangjinnanfu Hospital, Chengdu, China,

Abstract

Real-world testing and treatment patterns among patients with stage IV non-small cell lung cancer: A retrospective observational study.

Org: Integra Connect PrecisionQ, Massachusetts General Hospital, Sarah Cannon Research Institute/Tennessee Oncology, Florida Cancer Specialists and Research Institute, Ocala, FL, Thermo Fisher Scientific,

Abstract

Effectiveness of a pharmaceutical consultation in the care of cancer patients receiving oral anti-cancer therapy: PHACON study.

Org: Military Hospital Begin, Hospital Military Begin, Hôpital d’Instruction des Armées de Bégin, Clinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,

Abstract

Identification of SNVs via targeted comprehensive genome profiling in patients with brain cancer.

Org: One Cell Dx, School of Consciousness Studies, MIT-WPU, Pune, India, Dr. D.Y. Patil Vidyapeeth, OneCell Dx,

Abstract

Clinical efficacy and safety of immune checkpoint inhibitor in combination with regorafenib therapy as second⁃line regimen for patients with unresectable hepatocellular carcinoma.

Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Shandong Cancer Hospital and Institute, Jinan, shandong, China, Shandong Cancer Hospital and Institute, Jinan, China,

Abstract

A comparative study evaluating the quality of life in patients receiving chemotherapy versus oral TKI in the third line and beyond setting for advanced non–small-cell lung cancer.

Org: Tata Memorial Centre, Tata Memorial Hospital (HBNI),

Abstract

Stopping study in chronic myeloid leukemia: Defining a new paradigm for Ontario CML1.

Org: Windsor Regional Cancer Centre, Western University,

Abstract

Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma.

Org: The First Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, the Naval Medical University, National Center for Liver Cancer,

Abstract

Efficacy of subsequent immunotherapy-tyrosine kinase inhibitor combinations after TKI monotherapy failure in patients with intermediate/poor risk metastatic clear cell renal cell carcinoma: A real-world retrospective study.

Org: Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Pek, Beijing, China, Cancer Hospital of HuanXing Chaoyang District Beijing, Beijing, People's Republic of China., National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,

Abstract

Identification of novel actionable SNVs via targeted comprehensive genome profiling in patients with gallbladder and cholangiocarcinoma cancer.

Org: Bhaktivedanta Hospital And Research Centre and School of Consciouness, MIT WPU, OneCell Dx, Indx Technology, Artemis Hospital Gurgaon,

Abstract

Treatment of newly developed metastases after definitive chemoradiotherapy +/- ICI for unresectable stage III NSCLC.

Org: Department of Radiotherapy and Radiation Oncology, University Hospital, LMU Munich, Munich, Germany, Department of Radiotherapy and Radiation Oncology, University Hospital, LMU Munich, Munich, Bavaria, Germany, Ludwig-Maximilians-University of Munich and Thoracic Oncology Centre, Munich, Germany, Thoracic Oncology, Asklepios Clinics Munich-Gauting, Gauting, Germany, Thoracic Oncology, Asklepios Clinics Munich-Gauting, Germany, Gauting, Germany,

Abstract

Association between time to treatment initiation and survival in metastatic renal cell cancer: A population-based study of 5,193 cases from the California Cancer Registry (2010-2019).

Org: Hoag Family Cancer Institute and University of Southern California, Cancer Registry of Greater California (CRGC), Public Health Institute, United Arab Emirates University, Alain, United Arab Emirates, University of California Irvine,

Abstract

ADC vs HP dual-antibody for HER2-positive advanced breast cancer after failed to TKI.

Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China, Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China, Department of Breast Cancer, the Fifth Medical Center Affiliated to PLA General Hospital, Beijing, China,

Product

TKI (BRAF, MEK inhibitors)

Abstract

Comprehensive plasma genotyping reveals mutational signatures that confer resistance to tyrosine kinase inhibitors (TKI) in patients with advanced lung cancer.

Org: OneCell Dx, Tata Memorial Hospital (HBNI), OneCell Diagnostics, School of Consciousness, MIT WPU, Indx Technology,

Abstract

Comprehensive plasma genotyping of patients with EGFR positive NSCLC as a monitoring tool for therapy response and disease progression.

Org: One Cell Dx, Tata Memorial Hospital (HBNI), OneCell Dx, Tata Memorial Centre, Indx Technology,

Clinical trial

Phase II Pilot Study Evaluating Strategies to Overcome Resistance at the Time of Progression for Patients With Non-small Cell Lung Cancers Harboring Major Oncogenic Drivers

Status: Terminated, Estimated PCD: 2018-01-08